#26: Jason: AVANT's Partner, GlaxoSmithKline, Announces New Data Published in The Lancet Show That Rotarix(R) Provides Sustained and Broad Protection During the First Two Years of Life(1)
Note: Shares of AVAN declined amidst positive release of information on a clinical... |
November 26, 2007
12:37:49 PM |
#25: NewsBot: AVAN News AVANT Reports Fourth Quarter and Fiscal 2006 Financial Results
NEEDHAM, Mass.--(BUSINESS WIRE)--AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN)... |
March 7, 2007
05:00:00 AM |
#24: NewsBot: AVAN News AVANT to Report Fourth Quarter and Year-End Fiscal 2006 Financial Results on March 7, 2007
NEEDHAM, Mass.--(BUSINESS WIRE)--AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN)... |
March 5, 2007
03:38:00 PM |
#23: NewsBot: AVAN News AVANT Immunotherapeutics Reports Third Quarter and Nine-Month Financial Results
NEEDHAM, Mass.--(BUSINESS WIRE)--AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN)... |
November 1, 2006
05:00:00 AM |
#22: NewsBot: AVAN News AVANT To Present At Rodman & Renshaw 8th Annual Healthcare Conference
NEEDHAM, Mass.--(BUSINESS WIRE)--AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN)... |
October 31, 2006
05:00:00 AM |
#21: NewsBot: AVAN News AVANT to Report Third Quarter Fiscal 2006 Financial Results on November 1, 2006
NEEDHAM, Mass.--(BUSINESS WIRE)--AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN)... |
October 25, 2006
07:30:00 AM |
#20: NewsBot: AVAN News Avant Signs Agreement with Pfizer for Development of Animal Health Vaccines
NEEDHAM, Mass.--(BUSINESS WIRE)--AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN)... |
October 4, 2006
05:00:00 AM |
#19: NewsBot: AVAN News Fiscal 2007 Defense Appropriations Bill Dedicates $2.6 Million to Ongoing Development of AVANT's Oral Anthrax/Plague Combination Vaccine
NEEDHAM, Mass.--(BUSINESS WIRE)--AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN)... |
October 2, 2006
05:00:00 AM |
#18: NewsBot: AVAN News AVANT Immunotherapeutics Receives NIH SBIR Phase 2 Award for Development and Manufacture of Ty800 with VitriLife(R)
NEEDHAM, Mass.--(BUSINESS WIRE)--AVANT Immunotherapeutics, Inc. (NASDAQ: AVAN)... |
September 27, 2006
05:00:00 AM |
#17: NewsBot: AVAN News AVANT Announces Latest GSK Report on Sales of Rotarix(R) Evidences Disagreement on Royalty Rate in Patent Countries
NEEDHAM, Mass.--(BUSINESS WIRE)--Sept. 20, 2006--AVANT Immunotherapeutics, Inc.... |
September 20, 2006
05:41:00 AM |
#16: NewsBot: AVAN News AVANT Immunotherapeutics Reports Second Quarter and Six-Month Financial Results
NEEDHAM, Mass.--(BUSINESS WIRE)--Aug. 2, 2006--AVANT Immunotherapeutics, Inc.... |
August 2, 2006
05:00:00 AM |
#15: NewsBot: AVAN News AVANT's CholeraGarde(R) Vaccine Development Program Receives Further Funding from the Gates Foundation; New Support Follows Successful Phase 2 Clinical Trials
NEEDHAM, Mass.--(BUSINESS WIRE)--Aug. 2, 2006--AVANT Immunotherapeutics, Inc.... |
August 2, 2006
04:45:00 AM |
#14: NewsBot: AVAN News AVANT to Report Second Quarter Fiscal 2006 Financial Results on August 2, 2006
NEEDHAM, Mass.--(BUSINESS WIRE)--July 26, 2006-- - Conference Call to Follow... |
July 26, 2006
05:00:00 AM |
#13: NewsBot: AVAN News New Congressional Defense Bill Supports Development and Purchase of Vaccines to Meet the Nation's Public Health Threats; AVANT Expects to Participate in the Development of New Vaccine Technologies to Meet These Threats
NEEDHAM, Mass.--(BUSINESS WIRE)--Dec. 22, 2005--AVANT Immunotherapeutics, Inc.... |
December 22, 2005
12:00:00 PM |
#12: NewsBot: AVAN News AVANT Immunotherapeutics Announces that Rotarix(R) Rotavirus Vaccine Has Received a Positive Opinion from the European Regulatory Authorities; Partner GlaxoSmithKline Biologicals Seeking to Commercialize Rotarix(R) in Europe in First Half of 200
NEEDHAM, Mass.--(BUSINESS WIRE)--Dec. 15, 2005--AVANT Immunotherapeutics (Nasdaq:... |
December 15, 2005
08:44:00 AM |
| 
| 
| 
| 
| 
| 
